Beta blockers will lead Prinzmetal angina therapeutics sales through 2036 with 27.8% of the drug class segment in 2026. The market was valued at USD 11.8 billion in 2025 and is expected to reach USD 19.87 billion by 2036, creating an incremental opportunity of USD 7.5 billion between 2026 and 2036.